PART I Overview Our mission is to discover new medicines that improve the lives of people facing serious muscle disease. At Edgewise, we appreciate the life-limiting impact of serious muscle diseases. Our science-driven culture places patients first as we start with their unmet needs and then work towards developing therapies to help address the significant challenges of serious muscle diseases. Guided by our holistic drug discovery approach to targeting the muscle as an organ, we have combined ...
Q2 FY2026 — expected 2026-08-08
| Type | Subject | Detail | Quarter |
|---|---|---|---|
| topic_mention | EWTX | discussed_in_filing Cybersecurity | |
| topic_mention | EWTX | discussed_in_filing Trusted Computing | |
| topic_mention | EWTX | discussed_in_filing Blockchain & Crypto | |
| topic_mention | EWTX | discussed_in_filing Capital Expenditure | |
| topic_mention | EWTX | discussed_in_filing Regulation | |
| topic_mention | EWTX | discussed_in_filing Healthcare & Bio | |
| topic_mention | EWTX | discussed_in_filing AI Compute | |
| topic_mention | EWTX | discussed_in_filing Platform & Ecosystem | |
| topic_mention | EWTX | discussed_in_filing Sovereign & Government | |
| topic_mention | EWTX | discussed_in_filing Cybersecurity | |
| topic_mention | EWTX | discussed_in_filing Trusted Computing | |
| topic_mention | EWTX | discussed_in_filing Blockchain & Crypto | |
| topic_mention | EWTX | discussed_in_filing Capital Expenditure | |
| topic_mention | EWTX | discussed_in_filing Regulation | |
| topic_mention | EWTX | discussed_in_filing Healthcare & Bio | |
| topic_mention | EWTX | discussed_in_filing AI Compute | |
| topic_mention | EWTX | discussed_in_filing Platform & Ecosystem | |
| topic_mention | EWTX | discussed_in_filing Sovereign & Government | |
| topic_mention | EWTX | discussed_in_filing Cybersecurity | |
| topic_mention | EWTX | discussed_in_filing Trusted Computing |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-26 | 2025-12-31 | 0001104659-26-020112 | EDGAR | 100K words |
| 2025-03-03 | 2024-12-31 | 0001558370-25-002006 | EDGAR | — |
| 2024-02-22 | 2023-12-31 | 0001558370-24-001467 | EDGAR | — |
| 2023-02-23 | 2022-12-31 | 0001558370-23-001895 | EDGAR | — |
| 2022-02-24 | 2021-12-31 | 0001558370-22-001850 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-06 | 2025-09-30 | 0001104659-25-107427 | EDGAR | 68K words |
| 2025-08-07 | 2025-06-30 | 0001558370-25-010655 | EDGAR | — |
| 2025-05-08 | 2025-03-31 | 0001558370-25-006857 | EDGAR | — |
| 2024-11-07 | 2024-09-30 | 0001558370-24-014762 | EDGAR | — |
| 2024-08-08 | 2024-06-30 | 0001558370-24-011477 | EDGAR | — |
| 2024-05-09 | 2024-03-31 | 0001544784-24-000056 | EDGAR | — |
| 2023-11-09 | 2023-09-30 | 0001558370-23-018427 | EDGAR | — |
| 2023-08-10 | 2023-06-30 | 0001558370-23-014410 | EDGAR | — |
| 2023-05-11 | 2023-03-31 | 0001558370-23-009268 | EDGAR | — |
| 2022-11-03 | 2022-09-30 | 0001558370-22-016149 | EDGAR | — |
| 2022-08-04 | 2022-06-30 | 0001558370-22-012067 | EDGAR | — |
| 2022-05-11 | 2022-03-31 | 0001558370-22-008235 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-02-26 | 0001104659-26-020108 | EDGAR | 2K words |
| 2025-11-20 | 0001104659-25-114660 | EDGAR | — |
| 2025-11-10 | 0001104659-25-109295 | EDGAR | — |
| 2025-11-06 | 0001104659-25-107419 | EDGAR | — |
| 2025-08-07 | 0001104659-25-074987 | EDGAR | — |
| 2025-06-26 | 0001104659-25-063028 | EDGAR | — |
| 2025-05-08 | 0001104659-25-045896 | EDGAR | — |
| 2025-04-02 | 0001104659-25-030870 | EDGAR | — |
| 2025-04-02 | 0001104659-25-030839 | EDGAR | — |
| 2025-03-03 | 0001104659-25-019498 | EDGAR | — |
78 total filings indexed. 51 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001710072 |
| Ticker | EWTX |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report